- email:registrations@informa-ls.com
- phone:+44(0)20 7017 7481
 |
Oncology Drug Discovery
20 - 21 March 2012
|
Oncology Drug Discovery 2012
Enhance your oncology drug discovery pipeline by uncovering novel high value oncology targets, pathways and target validation strategies
The latest and most exciting developments in the future of oncology drug discovery, novel target and pathway idenification, cancer metabolism, antibody-drug conjugates, epigenetics, target validation strategies, screening and profiling, overcoming drug resistance, cancer stem cells and combination therapies in oncology drug discovery will be presented.
Why is Oncology Drug Discovery a MUST ATTEND for 2012?
- Address the unmet oncology industry needs read more
- Identify novel high value cancer targets and pathways read more
- Explore advances in improving oncology target validation read more
- Understand cancer metabolism pathways read more
- Overcome oncology drug resistance read more
- Increase the prediction of drug efficacies in vivo read more
- Participate in our interactive round table focus sessions on protein kinases, cancer metabolism and targeted therapies drug discovery read more
Oncology Drug Discovery 2012 Conference Speakers: Leading International Oncology Experts from Industry and Academia
- Stephan K. Grant, Senior Director, Pfizer Oncology, Pfizer Worldwide Research & Development, USA
- Patrick Steigemann, Scientist, Bayer Pharma AG, Germany
- Loïc Vincent, Head of Pharmacology, Drug Discovery & Preclinical Development, Sanofi Oncology, France
- Jürgen Moll, Director Department of Pharmacology, Boehringer Ingelheim RCV GmbH & Co KG, Austria
- Patty Culp, Associate Director I, Abbott Biotherapeutics, USA
- Lenny Dang, Senior Director, Agios Pharmaceuticals Inc. USA
- Haiching Ma, Chief Technology Officer, Reaction Biology Corporation, USA
- Steve Davies, Site Director, Dundee, Merck Millipore,
- Derek Trezise, Director & Site Head, Essen Bioscience Ltd, United Kingdom
- Eric Trinquet, VP Product Development - R&D, Cisbio Bioassays, France
- Paul Diehl, Director of Business Development, Cellecta, Inc. USA
- John Hickman, IMI PREDECT Coordinator on behalf of Servier, France
- Jon Moore, Head of Biology, Vernalis, UK
- Sandra Verploegen, Sr. Scientist Translational Research & Pharmacology, Genmab B.V., The Netherlands
- Giulio Casi, Responsible for Targeted Cytotoxics Development, Philochem AG. Switzerland
- Robert O. Carlson, Vice President, Head of Research, Myrexis, Inc., USA
- Ruggero De Maria, Scientific Director, Regina Elena National Cancer Institute, Italy
- Cedric Gaggioli, Senior Post-Doctoral Fellow, INSERM U634, U.N.S. University of Nice, France
- Roberto Scatena, Institute of Biochemistry and Clinical Biochemistry, Catholic University, Italy
Targets and Tools 2012: Sponsors
Targets and Tools 2012: Exhibitors
Promotional Participant
Oncology Drug Discovery 2012: Media Partners
Oncology Drug Discovery is part of Drug Discovery Targets & Tools 2012
Oncology Drug Discovery Seminars
Evening Seminar, Discussion and Dinners | Tuesday 20 March 2012
Epigenentics: An Emerging Target Class in Oncology Drug Discovery
Seminar Leaders:
Peter Staller, Director of Oncology Research, Epitherapeutics, Denmark
Robert Brown, Epigenetics Unit, Imperial College London, UK
Keynote Presentation: Future Perspectives for Oncology Drug Discovery- Critical Review of Cutting Edge Developments in Oncology Drug Discovery
- What are the most promising emerging novel oncology targets?
- Tools and technological advances and their impact on oncology drug discovery
- Review and future perspectives for innovative therapies for personalised medicine, including targeted therapies and antibody drug conjugates
- Cancer metabolism and epigenetics as emerging areas for therapeutic targets
Stephan K. Grant, PhD, Senior Director, Pfizer Oncology, USA
Stephan Grant, PhD is a Senior Director, Pfizer Oncology and leads the Biochemistry and Primary Screening group at Pfizer La Jolla Laboratories. Dr. Grant’s research group provides the primary in vitro pharmacology support for preclinical cancer research projects, including drug discovery efforts on targeted protein kinase inhibitors.
Oncology Drug Discovery is part of Drug Discovery Targets & Tools 2012
Feeds | Like | Share    |
Dates and Venues
20 Mar 2012 - 21 Mar 2012
Andel's Hotel Berlin
Latest tweets
Join our linked in group - Drug Discovery Targets and Tools - Here and start networking with the conference attendees before the event!
Oncology Drug Discovery Event Sponsors
